Figure 2.

Change from baseline to Week 6 in I‐QoL total summary score^a in patients with (A) SCI and (B) MS. ***p < 0.001 vs. placebo. Data are LS mean ± SE. Data shown are for the randomized population. ^aBased on the MMRM model to assess difference in change from baseline between each aboBoNT‐A dose group (600 or 800 U) versus placebo with treatment group, visits (Weeks 6 and 12), treatment by‐visit interaction, stratification factors (etiology of NDOI [SCI or MS], prior intradetrusor use [BoNT‐A‐naïve or BoNT‐A‐non‐naïve]), treatment‐by‐visit‐by‐etiology group interaction, study as fixed effect variables, study baseline value as covariates, and patient as a random effect. The statistical model includes Weeks 6 and 12; only Week 6 results are presented. AboBoNT‐A, abobotulinumtoxinA; BoNT‐A, botulinum toxin type A; I‐QoL, incontinence quality of life; LS, least squares; MMRM, mixed‐model repeated measures; MS, multiple sclerosis; N, number of patients in treatment group; n, number of patients with data; NDOI, neurogenic detrusor overactivity incontinence; SCI, spinal cord injury; SE, standard error; U, units